Literature DB >> 31668822

Disease burden concerning hepatitis E-infected inpatients in Jiangsu province, China.

Tingting Cui1, Xuefeng Zhang2, Qiang Wang3, Na Yue3, Mengyun Zheng3, Donglei Wang3, Chunxiao Duan3, Xiaoge Yu3, Changjun Bao2, Renjie Jiang4, Shilin Xu4, Zhaohu Yuan5, Yunke Qian5, Liling Chen6, Hui Hang6, Zhong Zhang7, Hongmin Sun7, Hui Jin8.   

Abstract

OBJECTIVE: This study aimed to determine the disease burden of hepatitis E virus (HEV)-infected inpatients in Jiangsu province, China.
METHODS: Between July 1, 2016 and October 31, 2018, 1152 HEV-infected inpatients were identified from four cities in Jiangsu province, namely, Nanjing, Suzhou, Yancheng, and Zhenjiang. The disease burden comprised the economic burden and loss of health due to HEV infection. Factors influencing the disease burden were analyzed using univariate and multivariate analyses.
RESULTS: The average direct, indirect, and total economic burden for 1152 HEV-infected inpatients was US$ 4,986.40, US$ 1,507.28, and US$ 6,493.68, respectively, accounting for 46.66%, 14.11%, and 60.77% of per capita disposable income (PCDI) in Jiangsu province, respectively. The disease burden for HEV-infected inpatients with hepatitis B was significantly higher than that for other inpatients. The average EQ-5D utility value of 1152 HEV-infected inpatients was 0.72 ± 0.18 quality-adjusted life years (QALYs) and the average EQ-visual analogue score (EQ-VAS) was 0.66 ± 0.17 points. Multivariate analysis showed that the direct economic burden and the total economic burden were influenced by variables such as hospitalization days, outcomes, past history of other diseases, and regions (P < 0.05). It was estimated the direct economic burden, the indirect economic burden, and the total economic burden for all HEV-infected inpatients in Jiangsu province in 2018 was approximately US$ 9.2 million, US$ 2.8 million and US$ 12.0 million, respectively.
CONCLUSION: The disease burden of HEV infection in Jiangsu province is severe, and more attention should be paid to the prevention of hepatitis E and the treatment of comorbidities.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Disease burden; Hepatitis E; Inpatients; Jiangsu province of China

Year:  2019        PMID: 31668822     DOI: 10.1016/j.vaccine.2019.10.045

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  Seroprevalence of AIH-related autoantibodies in patients with acute hepatitis E viral infection: a prospective case-control study in China.

Authors:  Jian Wu; Naizhou Guo; Lifei Zhu; Xueyan Zhang; Cunquan Xiong; Jun Liu; Yanping Xu; Jun Fan; Jiong Yu; Qiaoling Pan; Jinfeng Yang; Hanying Liang; Xiuyuan Jin; Sunyi Ye; Wei Wang; Chengyuan Liu; Jinrong Zhang; Gongqi Li; Bin Jiang; Hongcui Cao; Lanjuan Li
Journal:  Emerg Microbes Infect       Date:  2020-02-10       Impact factor: 7.163

2.  In-patient Expenditure Between 2012 and 2020 Concerning Patients With Liver Cirrhosis in Chongqing: A Hospital-Based Multicenter Retrospective Study.

Authors:  Juntao Tan; Xuewen Tang; Yuxin He; Xiaomei Xu; Daoping Qiu; Jianfei Chen; Qinghua Zhang; Lingqin Zhang
Journal:  Front Public Health       Date:  2022-03-08

3.  Disease burden in patients with severe hand, foot, and mouth disease in Jiangsu Province: a cross-sectional study.

Authors:  Ying Han; Hong Ji; Wenqi Shen; Chunxiao Duan; Tingting Cui; Liling Chen; Hui Hang; Zhong Zhang; Hongmin Sun; Xuefeng Zhang; Hui Jin
Journal:  Hum Vaccin Immunother       Date:  2022-04-27       Impact factor: 4.526

4.  Predicting incidence of hepatitis E for thirteen cities in Jiangsu Province, China.

Authors:  Tianxing Wu; Minghao Wang; Xiaoqing Cheng; Wendong Liu; Shutong Zhu; Xuefeng Zhang
Journal:  Front Public Health       Date:  2022-10-03

5.  Economic Burden of Major Diseases in China in 2013.

Authors:  Xianyan Song; Lan Lan; Ting Zhou; Jin Yin; Qiong Meng
Journal:  Front Public Health       Date:  2021-05-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.